Back to top
more

CorMedix (CRMD)

(Delayed Data from NSDQ)

$11.64 USD

11.64
1,634,978

-0.03 (-0.26%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $11.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Dynavax Technologies (DVAX) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -20.29% and 14.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of -22.22% and 280.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in CorMedix (CRMD)

by Zacks Equity Research

CorMedix (CRMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

CorMedix (CRMD) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 33.33% and -89.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate CorMedix (CRMD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of -11.11% and 46.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

CorMedix (CRMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CorMedix (CRMD) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 17.39% and -11.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline

by Zacks Equity Research

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CorMedix (CRMD) Upgraded to Buy: Here's Why

by Zacks Equity Research

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Here's Why Momentum Investors Will Love CorMedix (CRMD)

by Zacks Equity Research

Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Jumps: Stock Rises 9.8%

by Zacks Equity Research

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Zacks Equity Research

CorMedix (CRMD) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) Jumps: Stock Rises 7.5%

by Zacks Equity Research

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

CorMedix (CRMD) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

CorMedix (CRMD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for April 22nd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 22nd

Zacks Equity Research

Will CorMedix Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor CorMedix

Zacks Equity Research

Editas Medicine (EDIT) Catches Eye: Stock Jumps 9%

by Zacks Equity Research

Editas Medicine (EDIT) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Zacks Equity Research

CorMedix (CRMD) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: CorMedix (CRMD) Q4 Earnings Expected to Decline

by Zacks Equity Research

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

CorMedix (CRMD) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CorMedix (CRMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.